Skip to main content
Fig. 1 | Translational Medicine Communications

Fig. 1

From: Comparative molecular cell-of-origin classification of diffuse large B-cell lymphoma based on liquid and tissue biopsies

Fig. 1

Workflow used to develop the DLBCL-CCS classifier. The DLBCL-CCS classifier was developed and assessed using a two-pronged, sequential approach. A total of 118 DLBCL samples were classified into disease subtypes (ABC, GBC or Type III using gene expression profiling (GEP) and calculation of an LPS. Samples of known subtypes (30 samples on either end of the LPS spectrum) were used to identify changes in genomic architecture at six genomic loci that could best discriminate between ABC and GCB subtypes (the EpiSwitch DLBCL-CCS). 58 samples with intermediate LPS scores (Type III) were used to assess the performance of the EpiSwitch DLBCL-CCS and the Fluidigm assays

Back to article page

Translational Medicine Communications

ISSN: 2396-832X

Contact us